
January 25, 2022 - ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series - OnDemand
Date of Release: March 1, 2022
Expiration Date: March 31, 2024
Credits offered: CME
Estimate time of completion: 1 hour
Course must be completed by the expiration date
Course Description:
In this session, Drs. Janessa Laskin and Laura Williamson will present a case of a 64-year-old female diagnosed with metastatic lung neuroendocrine carcinoma. She had been treated with chemotherapy and radiation, with some response but subsequent growth in multiple locations. Whole genome and transcriptome analysis of a metastatic chest wall mass was performed as part of the Personalized OncoGenomics Study. Molecular analysis revealed no targetable driver mutations and low tumour mutation burden, but gene expression signatures provided evidence for T cells and macrophages in the tumour sample. The combination of biomarkers made this patient eligible for an immunotherapy trial. An additional case with similar gene expression signatures, a pediatric chordoma patient found to have low tumour mutation burden but high tumour T cell infiltration, subsequently responded to immunotherapy. The use of whole genome and transcriptome profiling to examine the immune microenvironment and biomarkers for immunotherapy response will be reviewed. The design of an immunotherapy trial based on both DNA and RNA molecular markers will be discussed
Target Audience:
All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic and VICC consortia, and ACMG.
Learning Objectives:
At the conclusion of this session, participants should be able to:
- Describe the genomic methods used to care for this patient